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Abstract
Background: Indigenous populations of Australia and Canada experience disproportionately high rates of chronic
disease. Our goal was to compare cardiovascular (CVD) risk profile and diabetes complications from three recent
comprehensive studies of diabetes complications in different Indigenous populations in Australia and Canada.
Methods: We compared participants from three recent studies: remote Indigenous Australians (2002-2003, n = 37
known diabetes), urban Indigenous Australians (2003-2005, n = 99 known diabetes), and remote Aboriginal
Canadians (2001-2002, n = 188 known diabetes).
Results: The three groups were similar for HbA1c, systolic BP, diabetes duration. Although leaner by body-mass-
index criteria, remote Indigenous Australians displayed a more adverse CVD risk profile with respect to: waist-hip-
ratio (1.03, 0.99, 0.94, remote Indigenous Australians, urban Indigenous Australians, remote Canadians, p < 0.001);
HDL-cholesterol (0.82, 0.96, 1.17 mmol/L, p < 0.001); urine albumin-creatinine-ratio (10.3, 2.4, 4.5 mg/mmol); and C-
reactive protein. With respect to diabetes complications, microalbuminuria (50%, 25%, 41%, p = 0.001) was more
common among both remote groups than urban Indigenous Australians, but there were no differences for
peripheral neuropathy, retinopathy or peripheral vascular disease.
Conclusions: Although there are many similarities in diabetes phenotype in Indigenous populations, this
comparison demonstrates that CVD risk profiles and diabetes complications may differ among groups. Irrespective,
management and intervention strategies are required from a young age in Indigenous populations and need to be
designed in consultation with communities and tailored to community and individual needs.
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Background
The burden of type 2 diabetes, chronic kidney disease
(CKD) and cardiovascular disease (CVD) has had devas-
tating effects on Indigenous populations of both Austra-
lia and Canada, and there appear to be close similarities
in the disease presentation and impact between the Indi-
genous populations of these geographically disparate
continents. Both populations have earlier onset of
chronic conditions such as diabetes and CVD compared
to the non-Indigenous population, and chronic condi-
tions are the greatest single contributor to the prema-
ture mortality in both Indigenous populations [1-5].
Despite the high prevalence of diabetes, CVD and
CKD among Indigenous populations globally, there is
little published data from studies using detailed partici-
pant examinations for assessment of complications of
diabetes [6,7]. Diabetic nephropathy has been well
described in both Indigenous Australians and Canadians
[8,9], but there are fewer available data on retinopathy,
neuropathy and peripheral vascular disease (PVD). CVD
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Measure Remote Australian Urban Australian Remote Canadian
Dates 2002-2003 2003-2005 2001-2002
Waist Measured at the point midway between
the lowest rib margin and iliac crest, using
a non-stretch tape measure in a horizontal
plane at the end of expiration
Measured at the point midway between
the lowest rib margin and iliac crest, using
a non-stretch tape measure in a horizontal
plane at the end of expiration
Measured at the natural indentation
between the umbilicus and xiphoid process
as viewed from behind; using an inelastic
tape in horizontal plane over light clothing
Hip Measured at the point yielding the
maximum circumference over the buttocks
with the tape in a horizontal plane over
very light clothing
Measured at the point yielding the
maximum circumference over the buttocks
with the tape in a horizontal plane over
very light clothing
Measured at the point of maximum
extension of the buttocks as viewed from
the side; using an inelastic tape in
horizontal plane over light clothing
Weight Digital portable scale Seca digital portable scale (Model 767, Seca
Deutschland, Hamburg, Germany)
Balance beam scale (Health-o-meter Inc,
Bridgeview, USA)
Blood
pressure &
pulse
Automated Dinamap (Critikon XL, Johnson
and Johnson, USA)
Welch Allyn Spot Vital signs monitor (Welch
Allyn Medical Products, Skaneateles Falls,
USA)
Hand-held aneroid sphygmomanometer
Lipids Hitachi 917 (standard automated
colorimetric methods using commercial
reagents)
Hitachi 917 enzymatic Dextran sulfate - magnesium precipitation
of non-HDL cholesterol. Technicon RA-1000
and Technicon reagents for measurement
of cholesterol and triglyceride
HbA1c Cation exchange high performance liquid
chromatography (HPLC) on a Pharmacia
MonoS column (results traceable to DCCT
method)
Cation exchange high performance liquid
chromatography (HPLC) on a Pharmacia
MonoS column (results traceable to DCCT
method)
Bayer DCA point-of-care
Serum
creatinine
Not performed Kinetic Jaffe (Hitachi 917), prior to
introduction of creatinine assays traceable
to IDMS
Jaffe (Beckman Coulter Synchron LX20),
prior to introduction of creatinine assays
traceable to IDMS
Urine
albumin
Immunonephelometry (Beckman array 360) Immunonephelometry (Beckman array 360) Bayer DCA point-of-care
Urine
creatinine
Kinetic Jaffe (Hitachi 917) Kinetic Jaffe (Hitachi 917) Bayer DCA point-of-care
Homocys-
teine
HPLC after conversion to a fluorescent
derivative with ABDF (7-Fluoro-2,1,3-
benzoxadiazole-4-sulfonamide)
HPLC after conversion to a fluorescent
derivative with ABDF (7-Fluoro-2,1,3-
benzoxadiazole-4-sulfonamide)
Abbot IMx
CRP High sensitivity commercial assay (BN-II
Nephelometer; Dade Behring Diagnostics,
Lane Cove NSW; intra and inter assay CVs
of 1.9% and 4.4% respectively, with a lower
limit of detection of 0.16 mg/L).
High sensitivity, immunoturbidimetry
(Hitachi 917)
High sensitivity, Dade-Behring, BN-100
Nephelometer.
Neuropathy Peripheral neuropathy was defined as
present if two or more of the following
were abnormal: pressure perception test
(monofilament), vibration sensation (128 Hz
tuning fork), pain sensation, temperature
sensation, ankle deep tendon reflexes [14]
Peripheral neuropathy was defined as
present if two or more of the following
were abnormal: modified neuropathy
symptom score; modified neuropathy
disability score; pressure perception test; fall
in systolic blood pressure of ≥ 20 mmHg
after standing for 60s [15]
Modified Michigan Neuropathy Screening
Instrument (modification involved addition
of monofilament and removal of
questionnaire component). Scores range
from 0 to 9, and neuropathy defined as
present if score > 2.
Retinopathy Determined from chart review Digital retinal photographs, Topcon non-
mydriatic retinal camera (Model TRC-NW5,
Topcon Corporation, Tokyo, Japan). Images
graded by a single ophthalmologist at the
Centre for Eye Research Australia
(Melbourne, Australia) according to
simplified Wisconsin scale: no diabetic
retinopathy (DR), mild or moderate non-
proliferative DR (NPDR), severe NPDR or
proliferative DR, fundus pathology other
than DR. Retinopathy includes NPDR or
PDR in 1 or both eyes.
Digital retinal photographs, Topcon non-
mydriatic retinal camera (Model TRC-
NW100, Topcon Canada, Waterloo, Ontario,
Canada). Images graded at the Ocular
Epidemiology Grading Centre at the
University of Wisconsin according to scale
of mild NPDR, moderate or severe NPDR,
proliferative DR or macula edema.
PVD: Ankle
Brachial
Pressure
Index
Doppler (Hadeco Bidirectional Smartdop
20; Hayashi Denki Co. Ltd., Kawasaki, Japan)
and manual anaeroid sphygmomanometer
(Welch Allyn Medical Products, Skaneateles
Falls, USA)
Doppler probe (Dopplex High Sensitivity
Pocket Doppler Model D900, Huntleigh
Healthcare Pty Ltd, Hamilton Hill, WA,
Australia) and manual anaeroid
sphygmomanometer (Welch Allyn Medical
Products, Skaneateles Falls, USA)
Doppler stethoscope and manual anaeroid
sphygmomanometer.
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Page 2 of 10is the leading cause of premature mortality among Indi-
genous Australians and Canadians [1,4,5,10], and rates
of CVD and of CVD-related mortality appear to be
increasing among these populations, despite a reduction
in the non-Indigenous populations of both nations
[11-13].
In light of these apparent similarities in early onset
and high prevalence of both type 2 diabetes and CVD
among the Indigenous populations of Australia and
Canada, we aimed to compare cardiovascular risk profile
and microvascular complications of diabetes from three
recent comprehensive, although small clinical studies of
Aboriginal cohorts with diabetes from Australia and
Canada: 1) a remote Aboriginal community in Northeast
Arnhemland, Northern Territory, Australia; 2) the Dar-
win Region Urban Indigenous Diabetes (DRUID) Study,
Northern Territory, Australia; and 3) the Sandy Lake
Diabetes Complications Study, from a remote First
Nations community from northwestern Ontario, Canada
[14-16].
Methods
Participants
Methods for the three studies have been described pre-
viously [14,15,17-19]. In brief, the Australian remote
Aboriginal community is on an island approximately
550 km from Darwin (the capital city of the Northern
Territory) and has a centralised population of approxi-
mately 1500. This was the first community-wide screen-
ing for risk of diabetes and CVD to be conducted in this
community. The protocol was approved by the Joint
Human Research Ethics Committee (HREC) of the
Northern Territory Department of Health and Commu-
nity Services and Menzies School of Health Research,
which includes an Aboriginal sub-committee with the
right of veto for studies involving Indigenous Austra-
lians. The Community Council endorsed the study in
June 2001. The study was conducted from August 2001
to March 2002, with participants with diabetes returning
for assessment of diabetes complications in March-May
2002. Participants were aged 15 years and over. Anthro-
pometric measurements and fasting blood samples were
collected from 332 of the eligible 706 residents aged 15
and over; 40 participants (12%) were diagnosed with dia-
betes. At the time of the study, health care was delivered
by a community-controlled health organisation (funded
by the federal government), staffed by one resident gen-
eral practitioner, remote area nurses and Aboriginal
Health Workers, with visiting outreach specialist ser-
vices from Darwin (a 3 hour flight away).
The DRUID Study was a volunteer cohort of approxi-
mately 1000 urban Indigenous people from Darwin,
Australia, undertaken from September 2003 to March
2005. Darwin is a tropical port city of approximately
100,000 people located on the northern coast of Austra-
lia. Participants met the following eligibility criteria:
identified as Aboriginal or Torres Strait Islander; aged ≥
15 years; had resided within a specified geographical
region around Darwin for at least 6 months; and were
living in a private dwelling. The DRUID cohort repre-
sented approximately 14% of the estimated target popu-
lation, and therefore is not necessarily representative.
T h eD R U I Ds t u d yr e p r e s e n t sah e t e r o g e n e o u sa n d
diverse population group with significant ethnic admix-
ture (with ancestry including Aboriginal, Torres Strait
Islander, and a range of European and Asian ethnicities),
diversity in language, and participants from a broad
range of social and economic circumstances, from impo-
verished people living in insecure housing to senior pub-
lic servants and business leaders. Participants ranged
from those who had lived in Darwin all their lives to
those who had relocated from a remote Aboriginal com-
munity to Darwin within recent years (but not in the
previous 6 months). Participants accessed a variety of
primary health care providers, from private general
practitioners (45%), to Aboriginal health services (32%)
to nil (11%) [20]. Of the 99 participants with known dia-
betes reported here: 87% were of Aboriginal back-
ground, 7% were of Torres Strait Islander background
and 6% reported both Aboriginal and Torres Strait
Islander background; 50% reported at least one non-
Indigenous grandparent. The DRUID study was
approved by the same HREC as the remote Australian
study.
T h eC a n a d i a ns t u d yw a sT h eS a n d yL a k eD i a b e t e s
Complications Study, implemented as part of the
Sandy Lake Health and Diabetes Project, a population-
based cohort study involving participants aged 10 years
and over, with collection of baseline data from 1993-
1995 [21]. Crude diabetes prevalence was 17.2% in the
baseline survey (which involved 728 participants, 72%
of the eligible population). The Sandy Lake Diabetes
Complications Study involved community members
with type 2 diabetes and was performed from Septem-
ber 2001 to July 2002, with approval from the Sandy
Lake First Nation Band Council and University of Tor-
onto Ethics Review Committee. The community of
Sandy Lake, Ontario, is located about 2000 km north-
west of Toronto, in the subarctic boreal forest region
of central Canada, with a population of approximately
2300 Oji-Cree. Health care is delivered at a nursing
station operated by the federal government and staffed
by outpost nurse practitioners. The history of the com-
munity is similar to that of the remote Australian
community in that people of Sandy Lake previously led
a hunter-gatherer life in small, extended family groups,
with rapid lifestyle changes beginning mid-twentieth
century [22].
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For consistency across the three study groups, only
those with a previous diabetes diagnosis are included
here, not those newly diagnosed by the Australian stu-
dies. Remote Australian study: previous diabetes diagno-
sis confirmed from medical records, n = 37 (100% of
diabetic patients known to the clinic and currently living
in the community). Urban Australian Study: participants
classified as having known diabetes if a diagnosis was
self-reported and they were either on current diabetes
medication or their glucose values on 75 g oral glucose
tolerance test (OGTT) met the 1999 WHO criteria for
diabetes [23]. Both participants known to have diabetes
and those newly diagnosed with diabetes by the study
were invited to return to participate in additional tests
for assessment of diabetic complications, 79% of eligible
participants completed the complications assessment,
which was performed within 3 months of baseline
assessment for 79%, within 6 months for 93%. Only
those with previously diagnosed diabetes are presented
here (n = 99). Remote Canadian Study: all members of
the Sandy Lake community with type 2 diabetes were
invited to participate in the study. Several data sources
were used to identify individuals, including health clinic
records and records of the baseline research study (in
which OGTTs were used to diagnose diabetes). A total
of 188 of 250 (75%) eligible participants with diabetes
consented to the complications study [16].
Assessment of diabetes complications
The full protocols for assessment of diabetes complica-
tions have been previously described [14-16,18,19].
Table 2 Characteristics of participants with known diabetes across the 3 studies
Group 1: Remote
Australian (n = 37)
Group 2: Urban
Australian (n = 99)
Group 3: Remote Canadian
(n = 188)
p values
Group 1
vs 2
Group 1
vs 3
Group 2
vs 3
Age (years) 51 ± 8 53 ± 10 47 ± 13 0.25 0.078 < 0.001
Female Sex
§ 20 (54%) 75 (76%) 113 (60%) 0.014 0.494 0.008
Current Smoker
§ 17 (49%) 22 (26%) 93 (51%) 0.016 0.784 < 0.001
Diabetes Duration
(years)*
6 (1 - 15) 7.5 (0 - 36) 9 (0 - 42) 0.144 0.114 0.643
Weight (kg) 76.3 ± 14.0 86.4 ± 17.2 84.1 ± 16.7 0.002 0.008 0.279
Height (cm) 168.6 ± 8.5 163.4 ± 8.4 166.5 ± 8.6 0.002 0.180 0.004
BMI (kg/m
2) 26.7 ± 3.8 32.4 ± 6.1 30.2 ± 5.3 < 0.001 < 0.001 0.003
Waist (cm) 101.0 ± 9.7 108.8 ± 12.6 103.5 ± 10.8 0.001 0.199 < 0.001
Hip (cm) 98.0 ± 8.0 110.6 ± 13.4 110.5 ± 11.5 < 0.001 < 0.001 0.968
WHR 1.03 ± 0.07 0.99 ± 0.09 0.94 ± 0.07 0.014 < 0.001 < 0.001
Heart Rate (bpm) 76 ± 11 76 ± 11 71 ± 10 0.820 0.021 < 0.001
Systolic BP(mmHg) 131 ± 26 128 ± 18 125 ± 17 0.408 0.065 0.183
Diastol BP(mmHg) 76 ± 11 78 ± 10 74 ± 9 0.2112 0.315 < 0.001
HbA1c
† (%) 8.7 (7.8-9.6) 8.1 (7.7 - 8.4) 8.0 (7.7 - 8.3) 0.123 0.111 0.751
Total cholesterol
†
(mmol/L)
4.8 (4.5-5.0) 5.0 (4.8-5.3) 4.8 (4.6 - 4.9) 0.253 0.972 0.061
Triglycerides
†
(mmol/L)
2.4 (2.0-2.8) 2.4 (2.1 - 2.8) 1.7 (1.6 - 1.9) 0.935 < 0.001 < 0.001
HDL-cholesterol
†
(mmol/L)
0.82 (0.76-0.89) 0.96 (0.91-1.02) 1.17 (1.11-1.23) 0.006 < 0.001 < 0.001
Creatinine
† (umol/L) - 72.7 (67.8-77.9) 62.8 (60.1-65.8) - - < 0.001
eGFR (MDRD) - 83.6 (77.6-90.1) 107.1 (102-112) - - < 0.001
CRP
† (mg/L) 6.6 (4.7 - 9.3) 6.8 (5.7 - 8.1) 3.1 (2.6 - 3.6) 0.870 < 0.001 < 0.001
Homocysteine
†
(umol/L)
12.4(10.8-14) 10.2 (9.5-11.1) 7.1 (6.8 - 7.5) 0.016 < 0.001 < 0.001
Urine ACR
† (mg/
mmol)
10.3(5.7-18.5) 2.4 (1.6-3.8) 4.5 (3.6 - 5.6) 0.004 0.003 0.007
Data are mean ± standard deviation unless stated otherwise. Biochemistry is fasting.
§Data are n(%). *Data are median (range).
†Data are geometric mean (95% confidence interval).
BMI, body mass index; WHR, waist-hip ratio; BP, blood pressure; Diastol, diastolic; eGFR (MDRD), estimated glomerular filtration rate (Modification of Diet in Renal
Disease formula); CRP, C-reactive protein; ACR, albumin-creatinine ratio.
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dies for anthropometry, blood pressure, biochemistry
and assessment of diabetes complications (Table 1).
Regarding nephropathy, creatinine was not assessed in
the remote Australian study and was measured in the
other studies prior to introduction of creatinine assays
traceable to the international reference method of Iso-
tope Dilution Mass Spectrometry (IDMS), thus eGFR
was calculated using the “186” MDRD (modification of
diet in renal disease) formula (appropriate for creatinine
measurements not calibrated to IDMS). Urine albumin-
creatinine ratio (ACR) was assessed at the point-of-care
by DCA2000 (Bayer Diagnostics, Tarrytown, NY, USA)
in the remote Canadian study, which has been validated
against laboratory techniques (used in the Australian
studies) [24]. Microalbuminuria was defined as urine
ACR ≥ 2.5 and ≤ 25 mg/mmol in men and ≥ 3.5 and ≤
25 mg/mmol in women. Macroalbuminuria was defined
as ACR > 25 mg/mmol [25]. There were considerable
differences between studies for methods of neuropathy
assessment. Although the definition used in previous
publications for the two Australian studies differed
slightly, comparable data was collected by both studies
thus the definition of neuropathy for the remote Austra-
lian study could be revised to match that of urban
study. However as this was not possible for the Cana-
dian study, rates of neuropathy presented are as pub-
lished for each study previously. As use of 10 gm
monofilament is consistent across all studies, results are
presented in addition to that of the original peripheral
neuropathy assessment. Retinopathy was assessed by
digital retinal photography in both the urban Australian
and remote Canadian studies but by chart review in the
remote Australian study. All 3 studies utilised ankle bra-
chial pressure index (ABPI) and standardised claudica-
tion questionnaires for assessment of PVD. PVD was
defined as present if ABPI < 0.9 and/or claudication
symptoms were present (in all groups for the purposes
of this comparison, although the ABPI cut-point used
differed in previous publications for each study).
Statistical analysis
Data analysis was performed using Stata version 10.1
(Stata Corporation, TX, USA). Variables with distribu-
tions significantly different from normal were log trans-
formed. Data are presented as frequency (%), mean (S.
D.) or geometric mean (95% confidence interval). To
determine associations between variables across study
groups, Pearson chi-square tests (categorical variables)
or independent sample t-tests (continuous variables)
were conducted in the whole group as well as stratified
by gender, due to differences between groups in propor-
tion of female participants. Median duration of diabetes
was compared between groups on pair-wise comparison
using the Kruskal-Wallis test. Multiple regression analy-
sis of albuminuria was performed using the backwards
selection method, for groups combined and stratified by
study. Established risk factors and variables with p <
0.05 on univariate analysis were considered for entry
into the model. Model fit was assessed using likelihood
ratio-chi square. Statistical significance was accepted at
p < 0.05.
Results
A comparison of the characteristics of diabetic partici-
pants of the three study groups is presented in Table 2.
Rates of current cigarette smoking were higher in both
remote Indigenous Australians and Canadians compared
to urban Indigenous Australians. Duration of diabetes
was not significantly different across groups. Remote
Indigenous Australian participants had significantly
lower body mass index (BMI) than the other groups but
Table 3 Diabetes management in urban and remote Indigenous Australians and remote Indigenous Canadians
Group 1: Remote
Australian (n = 37)
Group 2: Urban
Australian (n = 94)
Group 3: Remote
Canadian (n = 188)
Diet/nil glucose-lowering medications 11 (30%) 9 (10%) 78 (41%)
Metformin 24 (65%) 52 (57%) 83 (44%)
†‡
Sulphonylurea 11 (30%) 32 (35%) 62 (33%)
Acarbose 0 2 (2%) 1 (0.5%)
Thiazolidinedione 0 6 (7%) 5 (3%)
Insulin 0 18 (19%)
† 34 (18%)
†
Aspirin* 16 (43%) 39 (43%) 36 (32%)
HMG CoA reductase inhibitor* 9 (24%) 35 (37%) 23 (20%)‡
ACE inhibitor or A2RA* 23 (62%) 59 (63%) 73 (64%)
Data are n (%).
† p < 0.0001 when compared to Group 1
‡ p < 0.05 compared to Group 2
*n = 114 for Remote Canadian group
HMG CoA, 3-hydroxy-3-methylglutaryl-CoA; ACE, angiotensin converting enzyme; A2RA, angiotensin-2 receptor antagonist.
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ference. The remote Canadian group also displayed sig-
nificantly lower BMI and waist-hip ratio compared to
the urban Indigenous Australian group. On stratification
by gender, differences between urban Australian and
remote Canadian participants for height (both genders)
and BMI (in women) were no longer significant, but dif-
ferences in waist and WHR remained significant in both
genders (higher in urban Australian participants). Differ-
ences between urban and remote Australian participants
remained significant for all anthropometric variables in
women and for weight, BMI, waist, hip (but not height
and WHR) in men. Results were similar when adjusted
for age and sex (data not shown).
Remote Canadian participants displayed a significantly
lower diastolic blood pressure than urban Indigenous
Australians and lower heart rate than both Australian
groups (Table 2), with differences remaining significant
on stratification by gender (except for male urban Aus-
tralians compared to remote Canadians).
The remote Australian group had significantly lower
HDL-cholesterol and higher urine ACR than both urban
Australians and remote Canadians. Of note, compared
to each of the Australian groups, the remote Canadian
group demonstrated higher HDL-cholesterol and lower
triglycerides, C-reactive protein (CRP) and homocys-
teine. However, compared to urban Indigenous Austra-
lians, remote Indigenous Canadians had higher urine
ACR (but better kidney function as determined by
MDRD formula for eGFR). Differences between urban
Australian and remote Canadian participants remained
for all biochemical variables on stratification by gender
with the exception of ACR for women.
A comparison of current diabetes management is pre-
sented in Table 3. The notable difference between the
groups is use of insulin, which was not used for any
remote Australian participants but was used to a similar
extent in both urban Indigenous Australians and remote
Canadians. Metformin was used more frequently in both
Australian groups than in the remote Canadian group.
Use of angiotensin converting enzyme inhibitors or
angiotensin 2 receptor antagonists was similarly high in
all groups. Of participants with micro or macro-albumi-
nuria, 80%, 73% and 73% respectively of remote Austra-
lians, urban Australians, remote Canadians were treated
with angiotensin converting enzyme inhibitors or angio-
tensin 2 receptor antagonists.
Table 4 describes the frequency of complications in
the three groups. Rates of microalbuminuria were higher
in both remote groups compared to the urban group.
Macroalbuminuria was similar for remote Canadians
and urban Indigenous Australians but higher for remote
Indigenous Australians. Both remote groups had greater
rates of neuropathy than the urban Indigenous group,
with the highest rate in the remote Canadian group (but
there were methodological differences between all 3 stu-
dies). When assessment was based on results of the
pressure perception test (the common neuropathy test
across the studies), there were no significant differences
in neuropathy between any of the groups; although rates
appeared to be higher in both remote groups than the
urban group, this difference was not significant. There
were no significant differences in rates of retinopathy or
PVD between the 3 groups, nor for rates of current foot
ulcer or previous lower extremity amputation. It was
notable that fewer remote Australian participants
Table 4 Complications of diabetes in urban and remote Indigenous Australians and remote Indigenous Canadians
Complication Group 1: Remote
Australian (n = 36*)
Group 2: Urban
Australian (n = 99
†)
Group 3: Remote
Canadian (n = 165
‡)
p values
Group 1 vs 2 Group 1 vs 3 Group 2
vs 3
Peripheral neuropathy 10 (28%)** 9 (9%) 68 (47%) 0.007 0.041 < 0.001
Abnormal 10 g monofilament 7 (19%) 8 (8%) 22 (15%) 0.067 0.566 0.091
Peripheral Vascular Disease 2 (5.4%) 12 (12%) 16 (11%) 0.334 0.418 0.750
Current foot ulcer 1 (3%) 6 (6%) 7 (5%) 0.447 0.578 0.702
Lower Extremity Amputation 0 2 (2%) 0 0.390 - 0.087
Retinopathy 2 (7%) 18 (22%) 31 (24%) 0.070 0.202 0.615
Microalbuminuria
†† 18 (50%) 24 (25%) 67 (41%) 0.001 0.098 0.007
Macroalbuminuria
‡‡ 8 (22%) 12 (13%) 23 (14%) 0.012 0.065 0.298
Data are n (%).
* n = 32 for PVD, 32 for neuropathy, 29 for retinopathy. Note methods differed for retinopathy (Table 1).
† n = 82 for retinopathy
‡n = 146 for neuropathy, 145 PVD, 142 foot ulcer, 144 amputation, 124 retinopathy.
**When definition of neuropathy in Group 1 is revised to be that of Group 2 then neuropathy in Group 1 is 19% (n = 6). Note methods differed for neuropathy
in Group 3 (Table 1).
††Comparison across groups excludes those with macroalbuminuria
‡‡Comparison across groups excludes those with microalbuminuria
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participants: 25% compared to 90%, p < 0.001. Logistic
regression (Table 5) revealed that rates of albuminuria
were independently higher in both remote Australians
and remote Canadians compared to urban Australians
with diabetes, after adjustment for systolic blood pres-
sure, HbA1c and diabetes duration. On stratification by
study group, determinants of albuminuria were similar
in each of the three groups: systolic blood pressure was
a significant determinant in each study group, while dia-
betes duration was an additional determinant in urban
Australians and remote Canadians, and HbA1c signifi-
cant in remote Australians (data not shown).
Discussion
Systematic reviews have drawn attention to the high
prevalence of diabetes, CVD and CKD among Indigen-
ous populations globally but studies from detailed clini-
cal examination of participants are limited, and much of
the available data stems from medical records or admin-
istrative databases [6,7]. This is an important gap
because syntheses of detailed clinical data from even
small cohorts may enhance our understanding of the
extent and nature of these conditions. We have reported
that although these Indigenous cohorts with diabetes
from Australia and Canada displayed similarities for
some key factors, there were significant differences for
both CVD risk factors and microvascular complications
of diabetes between groups. Rates of some CVD risk
factors were higher in remote Indigenous Australians -
central obesity (despite a lower BMI), dyslipidemia and
CRP. Although rates of retinopathy and neuropathy
were similar across the three groups, rates of nephropa-
thy were higher in both remote groups than in the
urban Australian group.
The three population groups reveal similarly common
anthropometric, metabolic and lifestyle factors such as
young age, mean HbA1c (8-8.7% across the groups),
duration of diabetes (median duration 6 to 9 years
across groups) and high rates of cigarette smoking (par-
ticularly in both remote groups with 50% current smo-
kers). Consistent with previous reports, obesity and
related comorbidities were also very common in all
groups [10,26]. Interestingly, all 3 groups displayed rela-
tively well controlled blood pressure, with mean values
within each group within the targets of systolic < 130
and diastolic < 80 mmHg. Medication use was similar
across the studies, with the exception of insulin, where
use was lower in the remote Australian group, and met-
formin which was used more frequently in both Austra-
lian groups than in the Canadian group.
When compared to population-based data for the
overall Australian population (from the AusDiab Study),
achievement of therapeutic targets by urban Indigenous
Australian participants with diabetes from the DRUID
study was better for blood pressure and total choles-
terol, but worse for glycemic control [15]. Although
poor, the proportion of DRUID participants meeting
glycemic therapeutic targets (HbA1c < 7%) was similar
to that reported in secondary care settings in Australia
[27,28], as well as in remote Northern Australian com-
munities [29,30]. Possible contributory factors to the
lower rate of achieving therapeutic targets for glycemic
control (compared to good rates of blood pressure con-
trol) in the Indigenous populations of the current study
include unmeasured factors such as psychosocial stress,
socio-economic disadvantage and access to medical care,
including access to diabetes education and support of
self-management in the use of insulin. It is possible that
more intensive use of insulin therapy could result in
improved glycemic control in these populations [31],
but an associated increase in culturally-appropriate dia-
b e t e se d u c a t i o na n ds u p p o r tw o u l dn e e dt ob eak e y
component of that management strategy. It is notable
that rates of angiotensin converting enzyme inhibitor
use were high across all 3 groups in the current study,
although use of HMG CoA reductase inhibitors was
only moderate. Rates of use of both of these classes of
medications were higher in the current study than in
the Aboriginal participants of the Fremantle Diabetes
Study [32], however that study was performed a decade
prior to the current studies. The greater use of angio-
tension converting enzyme inhibitors than of lipid-low-
ering medications in the current study may relate to the
higher rates of albuminuria than elevated LDL-choles-
terol in participants of the current study.
We reported a gradient of CVD and metabolic risk
factors across the three groups with respect to central
obesity, dyslipidemia and inflammatory markers with the
most abnormal values being among remote Australians.
The greater risk seen in remote compared to urban
I n d i g e n o u sA u s t r a l i a n si sc onsistent with previous
reports relating to both CVD and end-stage kidney
Table 5 Logistic regression of albuminuria (ACR ≥ 2.5
mg/mmol in men, ≥ 3.5 mg/mmol in women)
Odds Ratio 95% Confidence Interval
Urban Australian 1.00 -
Remote Australian 7.24 2.60 - 20.23
Remote Canadian 3.15 1.66 - 6.01
Systolic BP (mmHg) 1.05 1.03 - 1.06
HbA1c (%) 1.13 1.00 - 1.29
Diabetes Duration* (years) 1.76 1.27 - 2.45
n = 268
*log transformed
The following variables were considered for inclusion in the final model: age,
gender, weight, BMI, waist, current smoker, HbA1c, total cholesterol,
triglycerides, diabetes duration.
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ent in rates of ESKD in Indigenous Australians across
different regions of Australia [33], with higher rates in
remote than urban regions, associated with greater
socioeconomic disadvantage in remote communities
[34]. The high levels of CRP in remote Indigenous Aus-
tralians is consistent with previous reports
30, 31; similar
findings of higher inflammatory markers in urban India
were postulated to relate to high rates of socioeconomic
disadvantage [35-37]. Although CRP levels were lower
in remote Canadians than both Australian groups, mean
CRP was relatively high in all three groups. We have
reported that CRP levels were independently elevated in
participants with diabetes from the remote Canadian
study, with no difference in CRP levels between carriers
and non-carriers of the private polymorphism associated
with increased prevalence of diabetes in that population
(HNF1A G319S) in participants with diabetes [38]. We
have previously reported very high fibrinogen levels
among urban Indigenous Australian participants of the
current study, and that fibrinogen levels were indepen-
dently associated with CRP and HbA1c in that group
[39]. There were also differences in body build and body
composition across these population groups, with the
striking difference in anthropometric indices for remote
Indigenous Australians relating to lack of peripheral
adiposity, demonstrated by significantly lower hip cir-
cumferences than both urban Australians and remote
Canadians. To our knowledge, there are no published
data comparing Indigenous Australian and Canadian
communities for diabetes complications and CVD risk
factors, although there have been previous reports relat-
ing to ESKD and HbA1c in these populations [40,41].
A striking finding of the current study relates to albu-
minuria - an exception to the above described gradient
of risk from remote Indigenous Canadians to urban
Indigenous Australians to remote Indigenous Austra-
lians. Rates of albuminuria were higher in both remote
groups compared to the urban Australian group, with
risk of albuminuria remaining independently higher in
both remote groups after adjustment for other risk fac-
t o r s .T h i si sc o n s i s t e n tw i t hp r e v i o u sr e p o r t so fh i g h
rates of ESKD among Indigenous Australians and Cana-
dians and the remote-urban gradient for ESKD among
Indigenous Australians [34]. Of note, there were metho-
dological differences between the studies for ACR,
which was measured at the point-of-care in the Cana-
dian study but in the laboratory in the Australian stu-
dies, however the remote Australian study did report
good agreement between point-of-care and laboratory
methods, consistent with previous reports [24,42].
Rates of microvascular complications other than albu-
minuria were similar across the three groups. There was
no difference in neuropathy (by 10 gm monofilament),
PVD or retinopathy rates. The trend to lower retinopa-
thy rates among remote Australians could be explained
by methodological differences (data were collected by
chart review in that study compared to the use of retinal
photography in other groups). There was a difference
b e t w e e nt h eA u s t r a l i a ng r o ups in that a lower rate of
wearing footwear was evident in the remote compared
to the urban group, perhaps reflecting the relatively
recent European contact for the remote group and dif-
ferent lifestyles between these groups. However rates of
current foot ulcers did not differ between the three
groups. The similar rates of microvascular complications
of retinopathy and peripheral vascular disease across the
three population groups may relate to similarities in
HbA1c, but CVD risk factors show prominent differ-
ences between population groups. These differences
may translate to different CVD outcomes and thus
further study is required.
A limitation of this study is that the relatively small
sample size of the cohorts which represent three distinct
communities within Australia and Canada. It is fully
appreciated that although there are many similarities in
metabolic and CVD risks described here to those pre-
viously reported for other Indigenous groups within
Australia and Canada, the results of this study may not
reflect those of the general Indigenous populations of
Australia and Canada. The urban Indigenous group
were a volunteer cohort who represent only 14% of the
target population, thus we are unable to comment as to
whether they are representative of this population.
Nevertheless, the DRUID Study is the largest and most
comprehensive dataset on diabetes and related condi-
tions in an urban Indigenous population in Australia.
This is of importance as 73% of the Indigenous Austra-
lian population live in urban centres [43]. There is a
similar paucity of data among urban Canadian Aborigi-
nal people for diabetes complications, thus the Austra-
lian data may be of international importance. There
were methodological differences between the three stu-
dies, particularly for assessment of blood pressure, neu-
ropathy, retinopathy and biochemical variables. We have
not assessed genetic factors, socioeconomic disadvan-
tage, psychosocial stress or access to medical care.
These factors likely play a role in the urban-remote dif-
ferences reported between the Australian groups: the
remote Australian group had less genetic admixture
than the urban Australian group and although Indigen-
ous Australians overall have lower incomes than non-
Indigenous Australians, incomes decrease with increas-
ing remoteness [1]. A recent review highlighted that
even in countries where a universal health system is in
place (such as Australia and Canada), socioeconomic
and ethnic inequalities have been reported in the provi-
sion of health-care to those with diabetes [44]. Although
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remote Australia, there may still be important barriers
for Indigenous Australians accessing these services, as
evident by reported delays for Indigenous Australians
accessing thrombolysis to a similar extent in both urban
and remote settings (compared to non-Indigenous Aus-
tralians) [45]. However the strength of this report is the
comprehensive clinical assessment of CVD risks and
diabetes complications using standardized techniques,
which was a feature of all three studies.
Conclusions
Despite similarly high rates of diabetes, associated com-
plications and premature CVD in these Indigenous
populations, several key CVD risk factors were higher in
the remote Australian group (central obesity, dyslipide-
mia, CRP) while albuminuria was notable for higher
rates in both remote Indigenous Australians and Cana-
dians than urban Indigenous Australians. In order to
address the increased risk of diabetes and CVD in Indi-
genous communities, action is required from a young
age both to prevent diabetes, and to improve manage-
ment once it is established. As there are important dif-
ferences in risk profile between Indigenous populations,
including within the one country, this action needs to
be designed and performed in partnership with commu-
nities and tailored to both community and individual
needs.
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